Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study

[1]  J. Yoon,et al.  The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011–2015 , 2019, Orphanet Journal of Rare Diseases.

[2]  R. Caporali,et al.  Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors , 2018, Modern rheumatology.

[3]  R. Landewé,et al.  Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort , 2018, The Journal of Rheumatology.

[4]  I. Olivieri,et al.  Challenges and Advances in Targeting Remission in Axial Spondyloarthritis , 2018, The Journal of Rheumatology.

[5]  M. Dougados,et al.  Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force , 2017, Annals of the rheumatic diseases.

[6]  M. Dougados,et al.  2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis , 2017, Annals of the rheumatic diseases.

[7]  H. Mann,et al.  A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study , 2014, Annals of the Rheumatic Diseases.

[8]  M. Dougados,et al.  A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis , 2015, Arthritis & rheumatology.

[9]  E. Martı́n-Mola,et al.  Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity , 2015, The Journal of Rheumatology.

[10]  M. Dougados,et al.  Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study , 2013, Annals of the rheumatic diseases.

[11]  V. Schabert,et al.  Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population , 2013, Journal of managed care pharmacy : JMCP.

[12]  S. Manganelli,et al.  Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients , 2013, Clinical Rheumatology.

[13]  F. Cantini,et al.  Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study , 2013, Biologics : targets & therapy.

[14]  A. Loft,et al.  Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry , 2012, Annals of the rheumatic diseases.

[15]  M. Brown,et al.  Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) , 2012, Annals of the rheumatic diseases.

[16]  R. Flipo,et al.  Dosage Adjustment of Anti-Tumor Necrosis Factor-α Inhibitor in Ankylosing Spondylitis Is Effective in Maintaining Remission in Clinical Practice , 2012, Journal of Rheumatology.

[17]  A. Loft,et al.  ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors , 2011, Annals of the rheumatic diseases.

[18]  M. Østergaard,et al.  Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry , 2010, Annals of the rheumatic diseases.

[19]  D. Symmons,et al.  Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register , 2009, Rheumatology.

[20]  John C. Davis,et al.  Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. , 2008, Arthritis and rheumatism.

[21]  M. Dougados,et al.  Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. , 2006, Arthritis and rheumatism.

[22]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[23]  J. Braun,et al.  Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab , 2005, Arthritis research & therapy.

[24]  J. Twisk,et al.  Longitudinal Data Analysis. A Comparison Between Generalized Estimating Equations and Random Coefficient Analysis , 2003, European Journal of Epidemiology.

[25]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[26]  John C. Davis,et al.  Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. , 2002, The New England journal of medicine.

[27]  H. Zeidler,et al.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.

[28]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.